Non-interventional Study With Nab-Paclitaxel (Abraxane®)

Non-Interventional Study to Investigate Efficacy and Safety of Nab-Paclitaxel in Patients With Metastatic Breast Cancer

The purpose of this non-interventional study is to collect data on the efficacy and safety of Nab-Paclitaxel in the routine application.

The main focus of this non-interventional study is set on answering the following questions:

• Can the results observed in controlled clinical trials regarding efficacy and safety be reproduced in the routine clinical setting?
• Are the side-effects of nab-paclitaxel therapy observed in this study comparable to the previously described safety-profile in terms of frequency and intensity?
• What are the main reasons for modification or termination of the nab-paclitaxel therapy?
• How does nab-paclitaxel therapy influence the patients' quality of life?
• What are the criteria for selecting nab-paclitaxel as therapy for metastatic breast cancer?

Inclusion Criteria:

• Female Patients with metastatic breast cancer, who are at least 18 years old (no upper age limit)

Exclusion Criteria:

• Contraindication according to the summary of product characteristics of Abraxane®
• No signed patient informed consent form available
• pregnant or breastfeeding patients.